CA2709380A1 - Cd24 as a brain tumor stem cell marker and a diagnostic and therapeutic target in primary neural and glial tumors of the brain - Google Patents

Cd24 as a brain tumor stem cell marker and a diagnostic and therapeutic target in primary neural and glial tumors of the brain Download PDF

Info

Publication number
CA2709380A1
CA2709380A1 CA2709380A CA2709380A CA2709380A1 CA 2709380 A1 CA2709380 A1 CA 2709380A1 CA 2709380 A CA2709380 A CA 2709380A CA 2709380 A CA2709380 A CA 2709380A CA 2709380 A1 CA2709380 A1 CA 2709380A1
Authority
CA
Canada
Prior art keywords
subject
tumor
brain
targeting component
specific targeting
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
CA2709380A
Other languages
English (en)
French (fr)
Inventor
Steven A. Goldman
Fraser Sim
Romane Melanie Auvergne
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Rochester
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA2709380A1 publication Critical patent/CA2709380A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2896—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against molecules with a "CD"-designation, not provided for elsewhere
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y10—TECHNICAL SUBJECTS COVERED BY FORMER USPC
    • Y10T—TECHNICAL SUBJECTS COVERED BY FORMER US CLASSIFICATION
    • Y10T436/00—Chemistry: analytical and immunological testing
    • Y10T436/14—Heterocyclic carbon compound [i.e., O, S, N, Se, Te, as only ring hetero atom]
    • Y10T436/142222—Hetero-O [e.g., ascorbic acid, etc.]
    • Y10T436/143333—Saccharide [e.g., DNA, etc.]

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Immunology (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Molecular Biology (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
CA2709380A 2007-12-21 2008-12-22 Cd24 as a brain tumor stem cell marker and a diagnostic and therapeutic target in primary neural and glial tumors of the brain Abandoned CA2709380A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US1638107P 2007-12-21 2007-12-21
US61/016,381 2007-12-21
PCT/US2008/087977 WO2009086284A1 (en) 2007-12-21 2008-12-22 Cd24 as a brain tumor stem cell marker and a diagnostic and therapeutic target in primary neaural and glial tumors of the brain

Publications (1)

Publication Number Publication Date
CA2709380A1 true CA2709380A1 (en) 2009-07-09

Family

ID=40824698

Family Applications (1)

Application Number Title Priority Date Filing Date
CA2709380A Abandoned CA2709380A1 (en) 2007-12-21 2008-12-22 Cd24 as a brain tumor stem cell marker and a diagnostic and therapeutic target in primary neural and glial tumors of the brain

Country Status (5)

Country Link
US (1) US20110002846A1 (https=)
EP (1) EP2231184A4 (https=)
JP (1) JP2011509244A (https=)
CA (1) CA2709380A1 (https=)
WO (1) WO2009086284A1 (https=)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HRP20201651T1 (hr) * 2015-05-07 2020-12-25 Oncoimmune, Inc. Uporaba cd24 za snižavanje razina lipoproteina niske gustoće kolesterola
CN114381491A (zh) * 2020-10-22 2022-04-22 复旦大学附属儿科医院 一种神经母细胞瘤相关的肿瘤细胞标志物及其应用
CN116478999B (zh) * 2023-01-16 2024-04-05 广西师范大学 免疫抑制分子cd24核酸适体的筛选及应用

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2556752C (en) * 2004-02-23 2016-02-02 Genentech, Inc. Heterocyclic self-immolative linkers and conjugates
JP4942643B2 (ja) * 2004-03-02 2012-05-30 シアトル ジェネティックス， インコーポレイテッド 部分的に付加された抗体およびそれらの結合体化方法
EP1766017B1 (en) * 2004-06-10 2015-01-21 Viventia Bio Inc. Tumor specific antibody
JP2008521828A (ja) * 2004-11-29 2008-06-26 シアトル ジェネティックス， インコーポレイテッド 操作された抗体およびイムノコンジュゲート
CA2632675A1 (en) * 2005-12-08 2007-07-05 Lionel J. Coignet Diagnostic and therapeutic strategies for conditions associated with the flj13639 gene
KR20080002341A (ko) * 2006-06-30 2008-01-04 재단법인서울대학교산학협력재단 Ｃｄ２４를 표적으로 하는 암 억제방법
WO2009063461A1 (en) * 2007-11-14 2009-05-22 The Medical Research, Infrastructure, And Health Services Fund Of The Tel Aviv Medical Center Methods of treating cancer using anti cd24 antibodies

Also Published As

Publication number Publication date
WO2009086284A1 (en) 2009-07-09
US20110002846A1 (en) 2011-01-06
JP2011509244A (ja) 2011-03-24
EP2231184A1 (en) 2010-09-29
EP2231184A4 (en) 2012-02-15

Similar Documents

Publication Publication Date Title
EP1613750B1 (en) Antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen and uses thereof
US7531171B2 (en) Antibodies to non-functional P2X7 receptor
JP7308191B2 (ja) 抗ｃｄ４７剤ベースの卵巣癌療法
US20040197325A1 (en) Antibodies against GPR64 and uses thereof
WO2003047623A1 (en) Treatment of prostate cancer by inhibitors of ncam2
KR102534098B1 (ko) 항암제 내성 진단 또는 치료용 조성물
US8093010B2 (en) Angiogenesis inhibiting molecules, their selection, production and their use in the treatment of cancer
EP1957115B1 (en) Method of treating ovarian and renal cancer using antibodies against t cell immunoglobulin domain and mucin domain 1 (tim-1) antigen
CN101932604A (zh) EphB4作为诊断标记和作为卵巢癌的治疗靶标的用途
WO2021155840A1 (zh) 抗pd-1抗体在治疗恶性肿瘤中的用途
CN114929263A (zh) 胞间黏附分子1（icam1）抗体药物缀合物及其用途
CN120826244A (zh) 含有抗ceacam5抗体-药物缀合物、抗vegfr-2抗体和抗pd1/pd-l1抗体的抗肿瘤组合
US20110002846A1 (en) Cd24 as a brain tumor stem cell marker and a diagnostic and therapeutic target in primary neural and glial tumors of the brain
KR20160141075A (ko) Claudin 7을 포함하는 방사선 반응성 위암 진단용 바이오마커 조성물
CA2420226C (en) Methods for treating demyelinating diseases
JP2025168424A (ja) 急性期の視神経脊髄炎の予防又は治療剤
ES2396672T3 (es) Forma constitutivamente activa del receptor Notch1 o un anticuerpo anti-receptor Notch1 para el tratamiento de cáncer de próstata
AU2001288286A1 (en) Methods for treating demyelinating diseases
US20250281609A1 (en) Composition for treating or preventing cancer
JP6854765B2 (ja) 標的への抗癌剤の送達を増加させる方法
US20050260132A1 (en) Monoclonal antibodies directed to receptor protein tyrosine phosphatase zeta
US8753630B2 (en) Using EGFRvIII to identify and target cancer stem cells
WO2025199292A1 (en) A humanized monoclonal antibody to sfrp2 for tumor associated macrophage reduction and polarization in cancer
TWI726228B (zh) Ｃｄ１４拮抗分子用於治療癌症
CN121108340A (zh) RORl的抗体及其制备方法和用途

Legal Events

Date Code Title Description
EEER Examination request

Effective date: 20131211

FZDE Discontinued

Effective date: 20161222